Servier Pharmaceuticals LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$49.8M
Doctors Paid
6,327
Transactions
16,957
2024 Total
$1.5M
Payment Breakdown by Category
Research$44.3M (89.0%)
Consulting$2.7M (5.4%)
Food & Beverage$423,236 (0.8%)
Travel$331,886 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $44.3M | 875 | 89.0% |
| Consulting Fee | $2.7M | 651 | 5.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $877,804 | 447 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $519,113 | 220 | 1.0% |
| Space rental or facility fees (teaching hospital only) | $449,628 | 64 | 0.9% |
| Food and Beverage | $423,236 | 12,845 | 0.8% |
| Travel and Lodging | $331,886 | 1,307 | 0.7% |
| Grant | $166,827 | 6 | 0.3% |
| Education | $18,792 | 541 | 0.0% |
| Honoraria | $1,000 | 1 | 0.0% |
Payments by Type
Research
$44.3M
875 transactions
General
$5.5M
16,082 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE I, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC, AND CLINICAL ACTIVITY STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES WITH AN IDH1 MUTATION | $19.9M | 0 | 123 |
| STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION | $10.2M | 0 | 70 |
| SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | $7.2M | 0 | 51 |
| STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | $2.9M | 0 | 437 |
| Treatment of Newly Diagnosed Acute LymphoblasticLeukemiain Children and Adolescents | $1.8M | 0 | 2 |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell LeukemiaLymphoma | $376,334 | 0 | 6 |
| Sponsored Research Agreement | $293,468 | 0 | 2 |
| PHASE II INVESTIGATOR SPONSORED STUDY OF CPX-351 IN COMBINATION WITH IVOSIDENIB FOR PATIENTS WITH IDH1 MUTATED ACUTE MYELOID LEUKEMIA OR HIGH-RISK MDS | $283,800 | 0 | 1 |
| STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | $254,505 | 0 | 55 |
| A STUDY ON DRUG MONITORING OF ASPARAGINASE ACTIVITY IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA | $170,727 | 0 | 4 |
| STUDY OF ORALLY ADMINISTERED AG-881 IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMAS, WITH AN IDH1 AND/OR IDH2 MUTATION | $163,908 | 0 | 37 |
| Preventing ASNase-associated pancreatitis using the novel dimension of metabolomics and proteomics | $163,600 | 0 | 1 |
| STUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS | $118,356 | 0 | 39 |
| Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy) | $108,554 | 0 | 19 |
| A Study on Drug Monitoring of Asparaginase Activity in Pediatric Patients with Acute Lymphoblastic Leukemia | $105,397 | 0 | 1 |
| STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS (CLARIDHY) (CLARIDHY) | $96,693 | 0 | 3 |
| Asparaginase Premedication, Hypersensitivity, and Therapeutic Drug Monitoring in Pediatric Patients with Acute Lymphoblastic Leukemia or Lymphoma | $76,175 | 0 | 3 |
| STUDY OF AG-120 (IVOSIDENIB) VS. PLACEBO IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA WITH AN IDH1 MUTATION (AGILE) | $20,094 | 0 | 13 |
| Updated Survival and Response Analyses From a Phase 1 Study of Ivosidenib or Enasidenib Combined With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed AML With an IDH1 or IDH2 Mutation | $6,374 | 1 | 2 |
| A STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA | $5,040 | 0 | 4 |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | $918.13 | 1 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Nawazish Khan, Md, MD | Hospitalist | Cerritos, CA | $249,750 | $0 |
| Ewa Matczak, Md, MD | Hematology & Oncology | Forest Hills, NY | $202,368 | $0 |
| Rebecca Johnson, Md, MD | Pediatric Hematology-Oncology | Tacoma, WA | $199,338 | $0 |
| Dr. Mitchell Cairo, Md, MD | Pediatric Hematology-Oncology | Hawthorne, NY | $167,773 | $0 |
| Dr. Dan Douer, M.d, M.D | Hematology | New York, NY | $155,548 | $0 |
| Javier Oesterheld, Md, MD | Pediatrics | Charlotte, NC | $139,432 | $0 |
| Michael Morse, M.d, M.D | Hematology & Oncology | Durham, NC | $120,980 | $0 |
| Dr. Scott Howard, Md, MD | Pediatric Hematology-Oncology | Memphis, TN | $112,552 | $0 |
| Scott Gottlieb, Md, MD | Internal Medicine | Stamford, CT | $90,000 | $0 |
| Dr. Thomas Leblanc, Md, Ma, MD, MA | Medical Oncology | Durham, NC | $82,749 | $0 |
| Harry Erba, Md, MD | Internal Medicine | Ann Arbor, MI | $76,170 | $0 |
| Rami Komrokji, M.d, M.D | Hematology | Tampa, FL | $53,253 | $0 |
| Dr. Courtney Dinardo, Md, MD | Internal Medicine | Houston, TX | $52,401 | $0 |
| Dr. Eytan Stein, M.d, M.D | Internal Medicine | New York, NY | $47,408 | $0 |
| Dr. Milind Javle, Md, MD | Medical Oncology | Houston, TX | $46,289 | $0 |
| Timothy Cloughesy, Md, MD | Neurology | Los Angeles, CA | $44,909 | $0 |
| Michael Bishop | Hematology & Oncology | Chicago, IL | $39,997 | $0 |
| Patrick Wen, Md, MD | Neurology | Boston, MA | $37,924 | $0 |
| Dr. Guillermo De Angulo, Md, MD | Pediatric Hematology-Oncology | Miami, FL | $37,876 | $0 |
| Natalie Bezler, M.d, M.D | Pediatric Hematology-Oncology | Hartford, CT | $37,026 | $0 |
| Dr. Joshua Strauss, M.d, M.D | Hematology & Oncology | Springfield, NJ | $35,484 | $0 |
| Daniel Orringer, M.d, M.D | Student in an Organized Health Care Education/Training Program | Ann Arbor, MI | $33,622 | $0 |
| Amir Fathi, M.d, M.D | Hematology & Oncology | Boston, MA | $33,535 | $0 |
| Dr. Ingo Mellinghoff, M.d, M.D | Internal Medicine | New York, NY | $33,175 | $0 |
| Mohammadbagher Ziari, Md, MD | Hematology & Oncology | Corona, CA | $30,908 | $0 |
About Servier Pharmaceuticals LLC
Servier Pharmaceuticals LLC has made $49.8M in payments to 6,327 healthcare providers, recorded across 16,957 transactions in the CMS Open Payments database. In 2024, the company paid $1.5M. The top product by payment volume is TIBSOVO ($38.6M).
Payments were distributed across 128 medical specialties. The top specialty by payment amount is Hematology & Oncology ($1.1M to 1,387 doctors).
Payment categories include: Food & Beverage ($423,236), Consulting ($2.7M), Research ($44.3M), Travel & Lodging ($331,886).
Servier Pharmaceuticals LLC is associated with 1 products in the CMS Open Payments database.